Abstract
Clinical depression and other mood disorders are relatively common mental illnesses but therapy for a substantial number of patients is unsatisfactory. For many years clinicians and neuroscientists believed that the evidence pointed toward alterations in brain monoamine function as the underlying cause of depression. This point of view is still valid. Indeed, much of current drug therapy appears to be targeted at central monoamine function. Other results, though, indicate that GABAergic mechanisms also might play a role in depression. Such indications stem from both direct and indirect evidence. Direct evidence has been gathered in the clinic from brain scans or postmortem brain samples, and cerebrospinal fluid (CSF) and serum analysis in depressed patients. Indirect evidence comes from interaction of antidepressant drugs with GABAergic system as assessed by in vivo and in vitro studies in animals. Most of the data from direct and indirect studies are consistent with GABA involvement in depression.
Similar content being viewed by others
REFERENCES
Schildkraut, J. J. 1965. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 122:509–522.
Duman, R. S. 1999. The neurochemistry of mood disorders: Preclinical studies. Pages 333-347, in Charney D. S., Nesler, E. J., and Bunney B. S. (eds.), Neurobiology of Mental Illness. Oxford University Press, New York, NY.
Garlow, S. J. 1999. The neurochemistry of mood disorders: Clinical studies. Pages 348-364, in CharneyD. S., Nesler, E. J. and BunneyB. S. (eds.), Neurobiology of Mental Illness. Oxford University Press, New York, NY.
Krnjevic, K. 1991. Significance of GABA in brain. Pages 47-87, in Tunnicliff, G. and Raess, B. U. (eds.), GABA Mechanisms Epilepsy. Wiley-Liss, New York, NY.
Paul, S. M. 1995. GABA and glycine. Pages 87-94, in Bloom, F. and Kupfer, D. (eds.), Psychopharmacology, the Fourth Generation of Progress. Raven Press, New York, NY.
Onteniente, B., Simon, H., Taghzouti, K., Geffard, M., Le Moal, M, and Calas, A. 1987. Dopamine-GABA interactions in the nucleus accumbens and lateral septum of the rat. Brain Res. 421:391–396.
Login, I. S., Pal, S. N., Adams, D. T., and Gold, P. E. 1998. Muscimol increases acetylcholine release by directly stimulating adult striatal cholinergic interneurons. Brain Res 779:33–40.
Van den Pol, A. N. and Obrietan, K. 2000. Neuromodulation of GABA in developing and mature hypothalamic neurons. Pages 409-438, in Martin, D. L. and Olsen, R. W. (eds.), GABA in the Nervous System: The View at Fifty Years. Lippcnott, Williams and Wilkins, Philadelphia, PA.
American Psychiatric and Association 1994. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association, Washington, D. C.
Robins, L. N., Helzer, J. E., and Weissman, M. M. 1987. Lifetime prevalance of specific psychiatric disorders in three sites. Arch. Gen. Psychiat. 44:152–156.
Black, D. W., Wanock, C., and Winokur, G. 1976. The Iowa linkage study I: Suicide and accidental deaths among psychiatric patients. Arch. Gen. Psychiat. 33:1029–1037.
Muller-Oerlinghausen, B., Muser-Causemann, B., and Volk, J. 1992. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J. Affect. Disord. 25:261–269.
Kovacs, M., Goldston, D., and Gatsonis, C. 1993. Suicidal behaviors and childhood-onset depressive disorders: A longitudinal investigation. J. Am. Acad. Child. Adolesc. Psychiatry 32:8–20.
Ahrens, B., Muller-Oerlinghausen, B., Schou, M., Wolf, T., Alda, M., Grof, E., Grof, P., Lenz, G., Simhandl, C., Thau, K. et al. 1995. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium pophylaxis. J. Affect. Disord. 33:67–75.
Dilsaver, S. C., Chen, Y. W., Swann, A. C., Shoaib, A. M., and Krajewski, K. J. 1994. Suicidality in patients with pure and depressive mania. Am. J. Psychiatry 151:1312–1315.
Weeke, A., Jule, K. and Veath, M. 1987. Cardiovascular death and manic depressive psychosis. J. Affect. Disord. 13:287–292.
Dilsaver, S. C. and Coffman, J. 1988. Depression and hypertension. Psychiatr. Res. 26:115–117.
Moldin, S. O., Reich, T., and Rice, J. P. 1991. Current perspectives on the genetics of unipolar depression. Behav. Genet. 21:211–242.
Nurnberger, J. I. and Berrettini, W. 2000. Psychiatric genetics. Pages 61-71, in Ebert, M. H., Loosen, P. T., and Nurcombe, B. (eds), Current Diagnostics in Psychiatry. Lange Medical Books/McGraw Hill, New York, NY.
Nurnberger, J. I. and Foroud, T. 2000. Genetics of bipolar affective disorder. Curr. Psychiatry Rep. 2:147–157.
Serretti, A., Macciardi, F., Cusin, C., Lattuada, E., Lilli, R., Di Bella, D., Catalano, M., and Smeraldi, E. 1998. GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. Psychiatr. Genet. 8:251–254.
Papadimitriou, G. N., Dikeos, D. G., Karadima, G., Avramopoulos, D., Daskalopoulou, E. G., Vassilopoulos, D., and Stefanis, C. N. 1998. Association between the GABA(A) receptor alpha5 subunit gene locus (GABRA5) and bipolar affective disorder. Am. J. Med. Genet. 81:73–80.
Papadimitriou, G. N., Dikeos, D. G., Karadima, G., Avramopoulos, D., Daskalopoulou, E. G., and Stefanis, C. N. 2001. GABA-A receptor beta3 and alpha5 subunit gene cluster on chromosome 15q11-q13 and bipolar disorder: A genetic association study. Am. J. Med. Genet. 105:317–320.
Tunnicliff, G. and Ngo, T. T. 1986. Regulation of γ-aminobutyric acid synthesis in the vertebrate nervous system. Neurochem. Int. 8:287–297.
Enna, S. J. and Bowery, N. J. 1997. The GABA Receptors. Humana Press, Towawa, NJ.
Krnjevic, K. and Schwartz, S. 1967. The action of gamma-aminobutyric acid on cortical neurones. Exp. Brain Res. 3:320–336.
Cherubini, E. and Strata, F. 1997. GABAC receptors: A novel receptor family with unusual pharmacology. News Physiol. Sci. 12:136–141.
Sodickson, D. L. and Bean, B. P. 1996. GABAB receptor-activated inwardly rectifying potassium current in dissociated hippocampal CA3 neurons. J. Neurosci. 16:6374–6385.
Ng, G. Y., Clark, J., Coulombe, N., Ethier, N., Hebert, T. E., Sullivan, R., Kargman, S., Chateauneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson, M. P., Liu, Q., Kolakowski, L. F., Jr., Evans, J. F., Bonner, T. I., and O'Neill, G. P. 1999 Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J. Biol. Chem. 274:7607–7610.
Liu, Q. R., Lopez-Corcuera, B., Mandiyan, S., Nelson, H., and Nelson, N. 1993. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain. J. Biol. Chem. 268:2106–2112.
Borden, L. A. 1996. GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem. Int. 29:335–356.
Radian, R., Bendahan, A., and Kanner, B. I. 1986. Purification and identification of the functional sodium-and chloride-coupled gamma-aminobutyric acid transport glycoprotein from rat brain. J. Biol. Chem. 261:15437–15441.
King, S. M. and Tunnicliff, G. 1990. Na+-and Cl--dependent [3H]GABA binding to catfish brain particles. Biochem. Int. 20:821–831.
Mehta, A. K. and Ticku, M. K. 1999. An update on GABAA receptors. Brain Res. Brain Res. Rev. 29:196–217.
Rabow, L. E., Russek, S. J., and Farb, D. H. 1995. From ion currents to genomic analysis: Recent advances in GABAA receptor research. Synapse 21:189–274.
Wong, G., Sei, Y., and Skolnick, P. 1992. Stable expression of type I gamma-aminobutyric acidA/benzodiazepine receptors in a transfected cell line. Mol. Pharmacol. 42:996–1003.
Valeyev, A. Y., Barker, J. L., Cruciani, R. A., Lange, G. D., Smallwood, V. V., and Mahan, L. C. 1993. Characterization of the gamma-aminobutyric acidA receptor-channel complex composed of alpha 1 beta 2 and alpha 1 beta 3 subunits from rat brain. J. Pharmacol. Exp. Ther. 265:985–991.
Hevers, W. and Luddens, H. 1998. The diversity of GABAA receptors: Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol. Neurobiol. 18:35–86.
De Blas, A. L. 1996. Brain GABAA receptors studied with subunit-specific antibodies. Mol. Neurobiol. 12:55–71.
Huntsman, M. M., Isackson, P. J., and Jones, E. G. 1994. Lamina-specific expression and activity-dependent regulation of seven GABAA receptor subunit mRNAs in monkey visual cortex. J. Neurosci. 14:2236–2259.
M cK ernan, R. M. and Whiting, P. J. 1996. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 19:139–143.
Bohlen, P., Huot, S., and Palfreyman, M. G. 1979. The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167:297–305.
Post, R. M., Ballenger, J. C., Hare, T. A., Goodwin, F. K., Lake, C. R., Jimerson, D. C., and Bunney, W. E. 1980. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res. Bull. 5:755–759.
Zimmer, R., Teelken, A. W., Meier, K. D., Ackenheil, M., and Zander, K. J. 1980. Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs. Prog. Neuropsychopharmacol. 4:613–620.
Roy, A., Dejong, J., and Ferraro, T. 1991. CSF GABA in depressed patients and normal controls. Psychol. Med. 21:613–618.
Gold, B. I., Bowers, M. B., Jr., Roth, R. H., and Sweeney, D. W. 1980. GABA levels in CSF of patients with psychiatric disorders. Am. J. Psychiatry 137:362–364.
Gerner, R. H. and Hare, T. A. 1981. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am. J. Psychiatry 138:1098–1101.
Berrettini, W. H., Nurnberger, J. I., Jr., Hare, T., Gershon, E. S., and Post, R. M. 1982. Plasma and CSF GABA in affective illness. Br. J. Psychiatry 141:483–487.
Gerner, R. H., Fairbanks, L., Anderson, G. M., Young, J. G., Scheinin, M., Linnoila, M., Hare, T. A., Shaywitz, B. A., and Cohen, D. J. 1984. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiatry 141:1533–1540.
Kasa, K., Otsuki, S., Yamamoto, M., Sato, M., Kuroda, H., and Ogawa, N. 1982. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol. Psychiatry 17:877–883.
Petty, F. and Schlesser, M. A. 1981. Plasma GABA in affective illness: A preliminary investigation. J. Affect. Disord. 3:339–343.
Petty, F. and Sherman, A. D. 1984. Plasma GABA levels in psychiatric illness. J. Affect. Disord. 6:131–138.
Petty, F., Kramer, G. L., Gullion, C. M., and Rush, A. J. 1992. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol. Psychiatry 32:354–363.
Petty, F., Kramer, G. L., Fulton, M., Moeller, F. G., and Rush, A. J. 1993. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 9:125–132.
Petty, F. 1994. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: A blood test for manic depressive disease? Clin. Chem. 40:296–302.
Petty, F., Kramer, G. L., Fulton, M., Davis, L., and Rush, A. J. 1995. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol. Psychiatry 37:806–810.
Petty, F., Fulton, M., Kramer, G. L., Kram, M., Davis, L. L., and Rush, A. J. 1999. Evidence for the segregation of a major gene for human plasma GABA levels. Mol. Psychiatry 4:587–589.
Devanand, D. P., Shapira, B., Petty, F., Kramer, G., Fitzsimons, L., Lerer, B., and Sackeim, H. A. 1995. Effects of electroconvulsive therapy on plasma GABA. Convuls. Ther. 11:3–13.
Mervaala, E., Kononen, M., Fohr, J., Husso-Saastamoinen, M., Valkonen-Korhonen, M., Kuikka, J. T., Viinamaki, H., Tammi, A. K., Tiihonen, J., Partanen, J., and Lehtonen, J. 2001. SPECT and neuropsychological performance in severe depression treated with ECT. J. Affect. Disord. 66:47–58.
Berrettini, W. H., Umberkoman-Wiita, B., Nurnberger, J. I., Jr., Vogel, W. H., Gershon, E. S., and Post, R. M. 1982. Platelet GABA-transaminase in affective illness. Psychiatry Res. 7:255–260.
Kaiya, H., Namba, M., Yoshida, H., and Nakamura, S. 1982. Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatry Res. 6:335–343.
Korpi, E. R., Kleinman, J. E., and Wyatt, R. J. 1988. GABA concentrations in forebrain areas of suicide victims. Biol. Psychiatry 23:109–114.
Cheetham, S. C., Crompton, M. R., Katona, C. L., Parker, S. J., and Horton, R. W. 1988. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res. 460:114–123.
Perry, E. K., Gibson, P. H., Blessed, G., Perry, R. H., and Tomlinson, B. E. 1977. Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34:247–265.
Honig, A., Bartlett, J. R., Bouras, N., and Bridges, P. K. 1988. Amino acid levels in depression: A preliminary investigation. J. Psychiatr. Res. 22:159–164.
Martin, D. L. and Tobin, A. J. 2000. Mechanisms controlling GABA synthesis and degradation in brain. Pages 25-41, in Martin, D. L., and Olsen, R. W. GABA in the Nervous System: The View at Fifty Years. Lippincott Williams and Wilkins, Philadelphia, PA.
Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R., Ji, F. Y., Kanbara, N., Kuzume, H., Sanbo, M., Yagi, T., and Obata, K. 1996. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65), maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem. Biophys. Res. Commun. 229:891–895.
Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R. G., Kanbara, N., Kuzume, H., Sanbo, M., Yagi, T., and Obata, K. 1997. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. USA 94:6496–6499.
Toth, Z., Bunney, W. E., Potkin, S. G., and Jones, E. G. 1999. Gene expression for glutamic acid decarboxylase is increased in prefrontal cortex of depressed patients. Soc. Neurosci. Abs. 29:2097.
Sanacora, G., Mason, G. F., Rothman, D. L., Behar, K. L., Hyder, F., Petroff, O. A., Berman, R. M., Charney, D. S., and Krystal, J. H. 1999. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 56:1043–1047.
SanacoraG., MasonG. F., RothmanD. L., and KrystalJ. H. 2002. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry 159:663–665.
Willner, P. 1984. The validity of animal models of depression. Psychopharmacology 83:1–16.
Willner, P. and Papp, M. 1997. Animal models to detect antidepressants. Pages 213-234, in SkolnickP. (ed.), Antidepressants: New Pharmacological Strategies Humana Press, Totowa, NJ.
Seligman, M. E. and Maier, S. F. 1967. Failure to escape traumatic shock. J. Exp. Psychol. 7:1–9.
Sherman, A. D. and Petty, F. 1982. Additivity of neurochemical changes in learned helplessness and imipramine. Behav. Neural. Biol. 35:344–353.
Poncelet, M., Martin, P., Danti, S., Simon, P., and Soubrie, P. 1987. Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals. Pharmacol. Biochem. Behav. 28:321–326.
Drugan, R. C., Maier, S. F., Skolnick, P., Paul, S. M., and Crawley, J. N. 1985. An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur. J. Pharmacol. 113:453–458.
Stanford, S. C., Taylor, S. C., and Little, H. J. 1987. Chronic desipramine treatment prevents the upregulation of cortical beta-receptors caused by a single dose of the benzodiazepine inverse agonist FG7142. Eur. J. Pharmacol. 139:225–232.
Martin, P., Pichat, P., Massol, J., Soubrie, P., Lloyd, K. G., and Puech, A. J. 1989. Decreased GABAB receptors in helpless rats: Reversal by tricyclic antidepressants. Neuropsychobiology 22:220–224.
Jancsar, S. M. and Leonard, B. E. 1984. Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 8:263–269.
Dennis, T., Beauchemin, V., and Lavoie, N. 1993. Differential effects of olfactory bulbectomy on GABAA and GABAB receptors in the rat brain. Pharmacol. Biochem. Behav. 46:77–82.
Lloyd, K. G., Morselli, P. L., Depoortere, H., Fournier, V., Zivkovic, B., Scatton, B., Broekkamp, C., Worms, P., and Bartholini, G. 1983. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol. Biochem Behav 18:957–966.
Porsolt, R. D., Le Pichon, M., and Jalfre, M. 1977. Depression: A new animal model sensitive to antidepressant treatment. Nature 266:730.
Willner, P. 1990. Animal models of depression: An overview. Pharmacol. Ther. 45:425–455.
Borsini, F., Evangelista, S., and Meli, A. 1986. Effect of GABAergic drugs in the behavioral ‘despair’ test in rats. Eur. J. Pharmacol. 121:26526–26528.
Nakagawa, Y., Ishima, T., Ishibashi, Y., Tsuji, M., and Takashima, T. 1996. Involvement of GABAB receptor systems in action of antidepressants: II. Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res. 728:225–230.
Borsini, F. and Meli, A. 1988. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147–160.
Lambert, J. J., Belelli, D., Hill-Venning, C., Callachan, H., and Peters, J. A. 1996. Neurosteroid modulation of native and recombinant GABAA receptors. Cell Mol. Neurobiol. 16:155–174.
Lambert, J. J., Belelli, D., Hill-Venning, C., and Peters, J. A. 1995. Neurosteroids and GABAA receptor function. Trends Pharmacol. Sci. 16:295–303.
Khisti, R. T., Chopde, C. T., and Jain, S. P. 2000. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5-alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67:137–143.
Nakagawa, Y., Ishima, T., Ishibashi, Y., Tsuji, M., and Takashima, T. 1996. Involvement of GABAB receptor systems in experimental depression: Baclofen but not bicuculline exacerbates helplessness in rats. Brain Res. 741:240–245.
Malatynska, E. and Kostowski, W. 1984. The effect of antidepressant drugs on dominance behavior in rats competing for food. Pol. J. Pharmacol. Pharm. 36:531–540.
Malatynska, E., De Leon, I., Allen, D., and Yamamura, H. I. 1995. Effects of amitriptyline on GABA-stimulated 36Cl- uptake in relation to a behavioral model of depression. Brain Res. Bull. 37:53–59.
Knapp, R. J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J., Miller, C., Crites, G., and Malatynska, E. 2002. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 440:27–35.
Malatynska, E., Goldenberg, R., Shuck, L., Haque, A., Zamecki, P., Crites, G., Schindler, N., and Knapp, R. J. 2002. Reductions of submissive behavior in rats: A test for antidepressant drug activity. Pharmacology 64:8–17.
Lloyd, K. G., Thuret, F., and Pilc, A. 1986. GABA and the mechanism of action of antidepressant drugs. L. E. R. S. 4:33–41.
Morselli, P. L., Fournier, V., Macher, J. P., Orofiamma, B., Botin, P., and Huber, P. 1986. Therapeutic action of progabide in depressive illness: A controlled clinical trial pp. 119-126 in Bartholini, G., Lloyd, K. G., and Morselli, P. L. (eds.), GABA and Mood Disorders: Experimental and Clinical Research. Raven Press, New York, NY.
Gottesfeld, Z. and Elliott, K. A. 1971. Factors that affect the binding and uptake of GABA by brain tissue. J. Neurochem. 18:683–690.
Iversen, L. L. and Johnston, G. A. 1971. GABA uptake in rat central nervous system: Comparison of uptake in slices and homogenates and the effects of some inhibitors. J. Neurochem. 18:1939–1950.
Weinstein, H., Varon, S., and Roberts, E. 1971. Effects of imipramine on the Na+-dependent exchange and retention of gamma-aminobutyric acid by mouse brain subcellular particles. Biochem. Pharmacol. 20:103–117.
Harris, M., Hopkin, J. M., and Neal, M. J. 1973. Effect of centrally acting drugs on the uptake of gamma-aminobutyric acid (GABA) by slices of rat cerebral cortex. Br. J. Pharmacol. 47:229–239.
Snodgrass, S. R., Hedley-Whyte, E. T., and Lorenzo, A. V. 1973. GABA transport by nerve ending fractions of cat brain. J. Neurochem. 20:771–782.
Olsen, R. W., Ticku, M. K., Van Ness, P. C., and Greenlee, D. 1978. Effects of drugs on gamma-aminobutyric acid receptors, uptake, release and synthesis in vitro. Brain Res. 139:277–294.
Pilc, A. and Lloyd, K. G. 1984. Chronic antidepressants and GABA “B” receptors: A GABA hypothesis of antidepressant drug action. Life Sci. 35:2149–2154.
Popov, N. and Matthies, H. 1969. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J. Neurochem. 16:899–907.
Patel, G. J., Schatz, R. P., Constantindies, S. M., and Lal, H. 1975. Effect of desipramine and pargyline on brain gamma-aminobutyric acid. Biochem. Pharmacol. 24:57–60.
Tunnicliff, G. 1976. Centrally-acting drugs and the formation of brain gamma-aminobutyric acid. Gen. Pharmacol. 7:259–262.
M cM anus, D. J., Baker, G. B., Martin, I. L., Greenshaw, A. J., and M cK enna, K. F. 1992. Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem. Pharmacol. 43:2486–2489.
Lloyd, K. G., Morselli, P. L., and Bartholini, G. 1987. GABA and affective disorders. Med. Biol. 65:159–165.
Suranyi-Cadotte, B. E., Dam, T. V., and Quirion, R. 1984. Antidepressant-anxiolytic interaction: Decreased density of benzodiazepine receptors in rat brain following chronic administration of antidepressants. Eur. J. Pharmacol. 106:673–675.
Suzdak, P. D. and Gianutsos, G. 1985. Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs: A possible role in affective disorders. Neuropharmacology 24:217–222.
Barbaccia, M. L., Ravizza, L., and Costa, E. 1986. Maprotiline: an antidepressant with an unusual pharmacological profile. J. Pharmacol. Exp. Ther. 236:307–312.
Squires, R. F. and Saederup, E. 1988 Antidepressants and metabolites that block GABAA receptors coupled to 35 S-t-butylbicyclophosphorothionate binding sites in rat brain. Brain Res. 441:15–22.
Squires, R. F. and Saederup, E. 1998. Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same ‘core’ fraction of GABA(A) receptors. Neurochem. Res. 23:1283–1290.
Medvedev, A. E., Shvedov, V. I., Chulkova, T. M., Fedotova, O. A., Saederup, E., and Squires, R. F. 1998. The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding. J. Neural. Transm. Suppl. 52:337–342.
Tunnicliff, G., Schindler, N. L., Crites, G. J., Goldenberg, R., Yochum, A., and Malatynska, E. 1999. The GABAA receptor complex as a target for fluoxetine action. Neurochem. Res. 24:1271–1276.
Malatynska, E., Serra, M., Ikeda, M., Biggio, G., and Yamamura, H. I. 1988. Modulation of GABA-stimulated chloride influx by beta-carbolines in rat brain membrane vesicles. Brain Res. 443:395–397.
Ikeda, M., Knapp, R. J., Malatynska, E., and Yamamura, H. I. 1989. Amoxapine inhibition of GABA-stimulated chloride conductance: Investigations of potential sites of activity. Life Sci. 45:1903–1910.
Malatynska, E., Crites, G., Yochum, A., Kopp, R., Giroux, M. L., and Dilsaver, S. C. 1998. Schild regression analysis of antidepressant and bicuculline antagonist effects at the GABAA receptor. Pharmacology 57:117–123.
Malatynska, E., Giroux, M. L., Dilsaver, S. C., and Schwarzkopf, S. B. 1991. Chronic treatment with amitriptyline alters the GABA-mediated uptake of 36Cl- in the rat brain. Pharmacol. Biochem. Behav. 39:553–556.
Malatynska, E., Miller, C., Schindler, N., Cecil, A., Knapp, A., Crites, G., and Rogers, H. 1999. Amitriptyline increases GABA-stimulated 36Cl- influx by recombinant (α1γ2) GABAA receptors. Brain Res. 851:277–280.
Boyer, P. A., Skolnick, P., and Fossom, L. H. 1998. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: A quantitative in situ hybridization study. J. Mol. Neurosci. 10:219–233.
Le Poul, E., Boni, C., Hanoun, N., Laporte, A. M., Laaris, N., Chauveau, J., Hamon, M., and Lanfumey, L. 2000. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39:110–122.
Tanay, V. A., Glencorse, T. A., Greenshaw, A. J., Baker, G. B., and Bateson, A. N. 1996. Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels. Neuropharmacology 35:1475–1482.
Tanay, V. M., Greenshaw, A. J., Baker, G. B., and Bateson, A. N. 2001. Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression. Mol. Psychiatry 6:404–412.
Reynolds, J. N. and Prasad, A. 1991. Ethanol enhances GABAA receptor-activated chloride currents in chick cerebral cortical neurons. Brain Res. 564:138–142.
Proctor, W. R., Soldo, B. L., Allan, A. M., and Dunwiddie, T. V. 1992. Ethanol enhances synaptically evoked GABAA receptor-mediated responses in cerebral cortical neurons in rat brain slices. Brain Res. 595:220–227.
Carlen, P. L., Gurevich, N., Davies, M. F., Blaxter, T. J., and O'Beirne, M. 1985. Enhanced neuronal K+ conductance: A possible common mechanism for sedative-hypnotic drug action. Can. J. Physiol. Pharmacol. 63:831–837.
Gage, P. W. and Robertson, B. 1985. Prolongation of inhibitory postsynaptic currents by pentobarbitone, halothane and ketamine in CA1 pyramidal cells in rat hippocampus. Br. J. Pharmacol. 85:675–681.
Mancillas, J. R., Siggins, G. R., and Bloom, F. E. 1986. Systemic ethanol: Selective enhancement of responses to acetylcholine and somatostatin in hippocampus. Science 231:161–163.
Siggins, G. R., Pittman, Q. J., and French, E. D. 1987. Effects of ethanol on CA1 and CA3 pyramidal cells in the hippocampal slice preparation: An intracellular study. Brain Res. 414:22–34.
Malatynska, E., Dilsaver, S. C., Knapp, R. J., Giroux, M. L., Ikeda, M., and Yamamura, H. I. 1991. The interaction of a benzodiazepine receptor antagonist (Ro15-1788) with GABA and GABA receptor antagonists at the GABAA receptor chloride-ionophore complex. Neurochem. Int. 18:405–410.
Schild, H. O. 1949. pA2 and competitive drug antagonism. Br. J. Pharmacol. 4:277–280.
Schild, H. O. 1957. Drug antagonism and pA2. Pharmacol. Rev. 9:242–246.
Kenakin, T. P. 1982. The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol. 60:249–265.
Malatynska, E., Crites, G. J., Harrawood, D., Goldenberg, R., and Matheson, G. K. 2000. Antidepressant effects on GABA-stimulated 36Cl- influx in rat cerebral cortex are altered after treatment with GABAA receptor antisense oligodeoxynucleotides. Brain Res. 869:78–84.
Malatynska, E., Matheson, G. K., Goldenberg, R., Crites, G. J., Schindler, N. L., Weinzapfel, D., Harrawood, D., Yochum, A., and Tunnicliff, G. 2000. Effects of treatment with GABA(A) receptor subunit antisense oligodeoxynucleotides on GABA-stimulated 36Cl- influx in the rat cerebral cortex. Neurochem. Int. 36:45–54.
Gunther, U., Benson, J., Benke, D., Fritschy, J. M., Reyes, G., Knoflach, F., Crestani, F., Aguzzi, A., Angoni, M., and Lang, Y. 1995. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. PNAS 92:7749–7753.
Crestani, F., Lorez, M., Baer, K., Essrich, C., Benke, D., Laurent, J. P., Belzung, C., Fritschy, J. M., Luscher, B. and Mohler, H. 1999. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci. 2:833–839.
Sur, C., Wafford, K. A., Reynolds, D. S., Hadingham, K. L., Bromidge, F., Macaulay, A., Collinson, N., O'Meara, G., Howell, O., Newman, R., Myers, J., Atack, J. R., Dawson, G. R., M cK ernan, R. M., Whiting, P. J., and Rosahl, T. W. 2001. Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. J. Neurosci. 21:3409–3418.
Skolnick, P. 1997. Introduction. Pages 10-11, in Skolnick, P. (ed.), Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, NJ.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tunnicliff, G., Malatynska, E. Central GABAergic Systems and Depressive Illness. Neurochem Res 28, 965–976 (2003). https://doi.org/10.1023/A:1023287729363
Issue Date:
DOI: https://doi.org/10.1023/A:1023287729363